Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

NCT04260022 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

242

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Chronic
Myeloid Leukemia
Chronic Myeloid Leukemia
Philadelphia Positive Acute Lymphoblastic Leukemia
B Cell Precursor Type Acute Leukemia

Interventions

DRUG: Ascentage Pharma HQP1351 bioavailable inhibitor
DRUG: Blinatumomab

Sponsor

Ascentage Pharma Group Inc.